94% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
CASE REPORT article
Front. Pharmacol.
Sec. Pharmacology of Anti-Cancer Drugs
Volume 16 - 2025 | doi: 10.3389/fphar.2025.1574286
This article is part of the Research TopicFrom Laboratory to Clinic: Novel Pharmacological Strategies for Cancer TreatmentView all articles
Excellent Efficacy of Trastuzumab Deruxtecan in a Patient with HER2-Positive Advanced Breast Cancer Complicated by Pulmonary Lymphangitic Carcinomatosis: A Case Report and Literature Review
Provisionally accepted- 1Sun Yat-sen Memorial Hospital, Guangzhou, Guangdong Province, China
- 2The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Trastuzumab deruxtecan (T-DXd or DS-8201), as a novel antibody-drug conjugate, has demonstrated good efficacy in HER2-positive advanced breast cancer. However, its effectiveness in treating pulmonary lymphangitic carcinomatosis (PLC) has not been reported. This paper presents a case of a HER2-positive advanced breast cancer patient who progressed after treatment with trastuzumab and pertuzumab. The patient developed multiple metastases along with PLC and subsequently received T-DXd treatment, achieving 14.2 months of progression-free survival (PFS). This case is the first to reveal the therapeutic potential of T-DXd in breast cancer patients with PLC.
Keywords: T-DXd, DS-8201, Advanced breast cancer, Pulmonary lymphangitic carcinomatosis, case report
Received: 10 Feb 2025; Accepted: 26 Mar 2025.
Copyright: © 2025 Luo, Chai, Ding and Tang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Lin Xiaoxiao Ding, Sun Yat-sen Memorial Hospital, Guangzhou, 510000, Guangdong Province, China
Song Tang, The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.